Hexamethylenetetramines Patents (Class 514/244)
-
Patent number: 10973800Abstract: The invention relates to salvinorin compositions and uses thereof. Specifically, the invention relates to administering a salvinorin compound to produce vasodilatory effect and organ protective effect from hypoxia/ischemia and reperfusion. The invention further relates to treating various diseases or disorders.Type: GrantFiled: June 29, 2011Date of Patent: April 13, 2021Assignee: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIAInventor: Renyu Liu
-
Patent number: 8969345Abstract: A dibenzoxepin derivative represented by the following general formula (I) wherein Y is a hydrogen atom and the like, RA is a hydrogen atom and the like, X is the formula (b3) wherein RB is a hydrogen atom and the like, and the like, A is the formula (a18) wherein R1 is a hydrogen atom and the like, and RC and RD are the same or different and each is a hydrogen atom and the like, and the like, which has a PPAR? agonist activity and the like, and useful as a therapeutic agent and/or prophylaxis agent and the like for type 2 diabetes and the like, or a pharmaceutically acceptable salt thereof and the like is provided.Type: GrantFiled: August 3, 2012Date of Patent: March 3, 2015Assignee: Kyowa Hakko Kirin Co., Ltd.Inventors: Keisuke Yamamoto, Tomohiro Tamura, Rina Nakamura, Kimihisa Ueno, Shintaro Hosoe
-
Publication number: 20150038480Abstract: The invention provides methods of preventing, treating or ameliorating autoimmune diseases, such as diabetes and celiac disease, by decreasing the binding of MHC class II molecules to antigenic peptides or fragments of antigenic peptides of the autoimmune disease by the administration of small organic compounds. The invention also provides pharmaceutical compositions comprising the therapeutically effective small organic compounds and methods of using the same.Type: ApplicationFiled: May 29, 2012Publication date: February 5, 2015Applicants: UNIVERSITY OF FLORIDA RESERCH FOUNDATION INCORPORTED, THE REGENTS OF THE UNIVERSITY OF COLORADO, a body corporateInventors: Aaron Michels, Maki Nakayama, David Ostrov
-
Patent number: 8900613Abstract: A biocidal composition comprising 2,2-dibromomalonamide and an aldehyde-based biocidal compound, and its use for the control of microorganisms in aqueous and water-containing systems.Type: GrantFiled: November 15, 2013Date of Patent: December 2, 2014Assignee: Dow Global Technologies LLCInventors: Bei Yin, Freddie L. Singleton
-
Patent number: 8754083Abstract: A biocidal composition comprising 2,2-dibromomalonamide and an aldehyde-based biocidal compound, and its use for the control of microorganisms in aqueous and water-containing systems.Type: GrantFiled: November 15, 2013Date of Patent: June 17, 2014Assignee: Dow Global Technologies LLCInventors: Bei Yin, Freddie L. Singleton
-
Patent number: 8747873Abstract: A biocidal composition comprising 2,2-dibromomalonamide and an aldehyde-based biocidal compound, and its use for the control of microorganisms in aqueous and water-containing systems.Type: GrantFiled: November 15, 2013Date of Patent: June 10, 2014Assignee: Dow Global Technologies LLCInventors: Bei Yin, Freddie L. Singleton
-
Patent number: 8748427Abstract: A biocidal composition comprising 2,2-dibromomalonamide and an aldehyde-based biocidal compound, and its use for the control of microorganisms in aqueous and water-containing systems.Type: GrantFiled: November 15, 2013Date of Patent: June 10, 2014Assignee: Dow Global Technologies LLCInventors: Bei Yin, Freddie L. Singleton
-
Publication number: 20140134275Abstract: The invention features compositions and methods that are useful for the treatment of neoplasia (e.g., pancreatic cancer, colon cancer, brain cancer) by increasing DNA damage, reducing nucleotide synthesis, and reducing base excision repair (BER).Type: ApplicationFiled: April 20, 2012Publication date: May 15, 2014Applicant: University of Florida Research FoundationInventors: Satya Narayan, Aruna S. Jaiswal, David A. Ostov, Sukwon Hong
-
Publication number: 20140135334Abstract: A biocidal composition comprising 2,2-dibromomalonamide and an aldehyde-based biocidal compound, and its use for the control of microorganisms in aqueous and water-containing systems.Type: ApplicationFiled: November 15, 2013Publication date: May 15, 2014Inventors: Bei Yin, Freddie L. Singleton
-
Publication number: 20140073646Abstract: A biocidal composition comprising 2,2-dibromomalonamide and an aldehyde-based biocidal compound, and its use for the control of microorganisms in aqueous and water-containing systems.Type: ApplicationFiled: November 15, 2013Publication date: March 13, 2014Inventors: Bei Yin, Freddie L. Singleton
-
Patent number: 8623854Abstract: A method of treating cancer in a subject comprising the step of administering to the subject in need thereof an effective amount of a combination of a compound that binds a nuclear export signal (NES inhibitor) on topoisomerase II? and a topoisomerase inhibitor. Twenty small molecule inhibitors (SMI) that bind to the two nuclear export sequences (NES) topo II? have been identified from the NCI database using computer-generated molecular modeling. These SMI will improve the effectiveness of topo II directed therapeutics, particularly in the treatment of diseases such as multiple myeloma (MM). In vitro apoptosis assays indicate that these drugs may be effective as single agents or in combination with currently used cancer drugs that target topo II.Type: GrantFiled: June 13, 2011Date of Patent: January 7, 2014Assignees: H. Lee Moffitt Cancer Center and Research Institute, Inc., University of Florida Research Foundation, Inc.Inventors: Daniel M. Sullivan, Joel G. Turner, Thomas C. Rowe, David A. Ostrov
-
Patent number: 8592396Abstract: Compounds are provided which are activators of the enzyme glucokinase and thus are useful in treating diabetes and related diseases, which compounds have the structure wherein R1, R2, R3, R4, R5, R6, Y and X are as defined herein or a pharmaceutically acceptable salt thereof. A method for treating diabetes and related disease employing the above compounds is also provided.Type: GrantFiled: April 14, 2011Date of Patent: November 26, 2013Assignee: Bristol-Myers Squibb CompanyInventors: Wei Meng, Peter T. W. Cheng
-
Patent number: 8466129Abstract: The present invention relates to methods of preventing airway remodeling using A2B adenosine receptor antagonists. This invention finds utility in the treatment and prevention of asthma, COPD, pulmonary fibrosis, emphysema, and other pulmonary diseases. The invention also relates to pharmaceutical compositions for use in the method.Type: GrantFiled: October 26, 2009Date of Patent: June 18, 2013Assignee: Gilead Sciences, Inc.Inventors: Dewan Zeng, Michael R. Blackburn, Luiz Belardinelli
-
Publication number: 20130079297Abstract: The invention relates to phosphorylation inhibitor compounds and methods of identifying and using them. The invention further relates to pharmaceutical compositions and methods for treating cell proliferative disorders, especially cancer.Type: ApplicationFiled: November 19, 2012Publication date: March 28, 2013Applicant: UNIVERSITY OF FLORIDA RESEARCH FOUNDATIONInventor: UNIVERSITY OF FLORIDA RESEARCH FOUNDA
-
Patent number: 8349834Abstract: This invention relates to certain unsaturated fatty acid derivatives of therapeutically active 1,3-dioxolane nucleoside analogues and to pharmaceutical formulations containing them. The said derivatives fall within formula (I). Compounds of formula (I) can be used in the treatment of a cancerous disease, including solid tumors and haematological cancers such as leukaemias, lymphomas and multiple myelomas.Type: GrantFiled: December 7, 2006Date of Patent: January 8, 2013Assignee: Clavis Pharma ASInventors: Finn Myhren, Marit Liland Sandvold, Steinar Hagen, Ole Henrik Eriksen
-
Patent number: 8222250Abstract: Compositions of 1-(3-chloroallyl)-3,5,7-triaza-1-azonia-adamantane chloride, and an optional second biocide, in copolymers of ethylene oxide/propylene oxide are provided. The compositions exhibit good color and phase stability.Type: GrantFiled: June 26, 2009Date of Patent: July 17, 2012Assignee: Dow Global Technologies LLCInventors: Ioana Annis, Suzanne DeBruhl, Heidie M. Jevey, Jon B. Raymond
-
Publication number: 20120141491Abstract: The subject application provides small compounds that are able to increase/enhance autophagy in various cells. These compounds are useful in augmenting existing treatments of various cancers, microbial/viral infections, and neurodegenerative diseases. Thus, the subject application also provides methods of treating various types of cancers, microbial/viral infections, and neurodegenerative diseases.Type: ApplicationFiled: August 9, 2010Publication date: June 7, 2012Applicant: University of Florida Research Foundation Inc.Inventors: William A. Dunn, Debra Everton Akin, Brian Keith Law
-
Publication number: 20120129861Abstract: A biocidal composition comprising 2,2-dibromomalonamide and an aldehyde-based biocidal compound, and its use for the control of microorganisms in aqueous and water-containing systems.Type: ApplicationFiled: September 27, 2010Publication date: May 24, 2012Inventors: Bei Yin, Freddie L. Singleton
-
Publication number: 20120100227Abstract: The invention relates to protein binding inhibitor compounds and methods of identifying and using them. The invention further relates to pharmaceutical compositions and methods for treating a variety of diseases and disorders, including cell proliferative disorders, especially cancer.Type: ApplicationFiled: March 4, 2010Publication date: April 26, 2012Applicant: University of Florida Research FoundationInventors: Vita Golubovskaya, David A. Ostrov, William G. Cance
-
Patent number: 8163865Abstract: Biocompatible amino acid anhydride polymers for use in tissue engineering, and methods for their preparation and use.Type: GrantFiled: August 6, 2009Date of Patent: April 24, 2012Assignee: University of WashingtonInventors: Shrojalkumar M. Desai, Buddy D. Ratner
-
Patent number: 8163911Abstract: The invention relates to substituted arylsulphonylaminomethylphosphonic acid derivatives of general formula (I) wherein the groups Ra to Rf, A and Z are defined as mentioned in the specification and claims, which are suitable for preparing a medicament for the treatment of metabolic disorders, particularly type 1 or type 2 diabetes mellitus.Type: GrantFiled: September 4, 2008Date of Patent: April 24, 2012Assignee: Boehringer Ingelheim International GmbHInventors: Elke Langkopf, Alexander Pautsch, Corinna Schoelch, Annette Schuler-Metz, Ruediger Streicher, Holger Wagner
-
Publication number: 20120046246Abstract: This invention relates to therapeutic methods for treating or preventing an osteoclast-related disease or disorder in a subject identified as in need of a treatment of bone diseases, compounds for such uses, and compositions thereof.Type: ApplicationFiled: December 18, 2009Publication date: February 23, 2012Applicant: University of Florida Research FoundationInventors: Lexie Shannon Holliday, David A. Ostrov
-
Publication number: 20110275581Abstract: A method of treating cancer in a subject comprising the step of administering to the subject in need thereof an effective amount of a combination of a compound that binds a nuclear export signal (NES inhibitor) on topoisomerase II? and a topoisomerase inhibitor. Twenty small molecule inhibitors (SMI) that bind to the two nuclear export sequences (NES) topo II? have been identified from the NCI database using computer-generated molecular modeling. These SMI will improve the effectiveness of topo II directed therapeutics, particularly in the treatment of diseases such as multiple myeloma (MM). In vitro apoptosis assays indicate that these drugs may be effective as single agents or in combination with currently used cancer drugs that target topo II.Type: ApplicationFiled: June 13, 2011Publication date: November 10, 2011Applicants: University of Florida Research Foundation, Inc., H. Lee Moffitt Cancer Center and Research Institute, Inc.Inventors: Daniel M. Sullivan, Joel G. Turner, Thomas C. Rowe, David A. Ostrov
-
Publication number: 20110070179Abstract: Compositions are disclosed comprising novel fluorinated cationic alcohols in a cosmetically acceptable vehicle. The fluorinated compounds alter a surface property of the hair to provide hair conditioning, for example. In embodiments, the compounds have improved water solubility and deposition properties.Type: ApplicationFiled: September 16, 2010Publication date: March 24, 2011Applicant: Living Proof, Inc.Inventors: David T. Puerta, Lorna Nagamoottoo-Casse, Kevin T. Love
-
Patent number: 7858625Abstract: This invention features conjugates, compositions, methods of synthesis, and applications thereof, including folate derived conjugates of nucleosides, nucleotides, non-nucleosides, and nucleic acids including enzymatic nucleic acids and antisense nucleic acid molecules.Type: GrantFiled: June 24, 2005Date of Patent: December 28, 2010Assignee: Sirna Therapeutics, Inc.Inventors: Jasenka Matulic-Adamic, Leonid Beigelman
-
Publication number: 20100310680Abstract: This invention relates to a novel composition and method useful for the treatment of acne, and more particularly, to a composition and method for reducing an appearance of post acne marks and scars without skin irritation in a short amount of time.Type: ApplicationFiled: June 9, 2009Publication date: December 9, 2010Inventors: Theresa Chen, Geraldine Watson, I-Ting Wu
-
Publication number: 20100166886Abstract: The invention features a method of (i) reducing the appearance of pores or oil on the skin and (ii) evening skin tone or smoothing skin by applying to an area of skin in need of such treatment a composition including an anti-acne agent, an antimicrobial agent, and a lactate.Type: ApplicationFiled: March 12, 2010Publication date: July 1, 2010Inventors: Jeffrey M. Wu, Jue-Chen Liu, Jeannette Chantalat, Ying Sun, Stefanie A. Johnsen, Hanuman B. Jampani
-
Patent number: 7745442Abstract: Prophylactic treatment methods are provided for protection of individuals and/or populations against infection from airborne pathogens. In particular, prophylactic treatment methods are provided including administering a sodium channel blocker or pharmaceutically acceptable salts thereof to one or more members of a population at risk of exposure to or already exposed to one or more airborne pathogens, either from natural sources or from intentional release of pathogens into the environment.Type: GrantFiled: August 18, 2004Date of Patent: June 29, 2010Assignee: Parion Sciences, Inc.Inventors: Michael R. Johnson, Samuel E. Hopkins
-
Publication number: 20090325965Abstract: Compositions of 1-(3-chloroallyl)-3,5,7-triaza-1-azonia-adamantane chloride, and an optional second biocide, in copolymers of ethylene oxide/propylene oxide are provided. The compositions exhibit good color and phase stability.Type: ApplicationFiled: June 26, 2009Publication date: December 31, 2009Inventors: Ioana Annis, Suzanne DeBruhl, Heidie M. Jevey, Jon B. Raymond
-
Publication number: 20090191285Abstract: A moisturizing liquid liner composition comprising a hydrophobic moiety and an emulsifier is described. Further, a substrate comprising a barrier layer and a moisturizing liquid liner composition comprising a hydrophobic moiety and an emulsifier is described. The substrate may be incorporated into an article.Type: ApplicationFiled: January 30, 2008Publication date: July 30, 2009Applicant: Evonik Degussa CorporationInventors: Anna HOWE, Dana Adkins, Scott W. Wenzel, David William Koenig, Douglas R. Hoffman
-
Patent number: 7507734Abstract: Disclosed are compounds according to the general formula (I), where the definitions of the substituents X, R1 and R2 are detailed in the description, as well as their physiologically acceptable salts and solvate, methods for producing these compounds and their use as pharmaceuticals. These compounds are kinase inhibitors, in particular inhibitors of the kinase CDK2 (cyclin-dependent kinase 2).Type: GrantFiled: November 16, 2006Date of Patent: March 24, 2009Assignee: Aventis Pharma S.A.Inventors: Swen Hoelder, Gunter Muller, Karl Schoenafinger, David William Will, Hans Matter, Martin Bossart, Cecile Combeau, Christine Delaisi, Ingrid Sassoon, Anke Steinmetz, Didier Benard
-
Patent number: 7323449Abstract: The present invention provides thionucleoside compounds and certain derivatives thereof which are inhibitors of RNA-dependent RNA viral polymerase. These compounds are inhibitors of RNA-dependent RNA viral replication and are useful for the treatment of RNA-dependent RNA viral infection. They are particularly useful as inhibitors of hepatitis C virus (HCV) NS5B polymerase, as inhibitors of HCV replication, and/or for the treatment of hepatitis C infection. The invention also describes pharmaceutical compositions containing such thionucleoside compounds alone or in combination with other agents active against RNA-dependent RNA viral infection, in particular HCV infection. Also disclosed are methods of inhibiting RNA-dependent RNA polymerase, inhibiting RNA-dependent RNA viral replication, and/or treating RNA-dependent RNA viral infection with the thionucleoside compounds of the present invention.Type: GrantFiled: July 18, 2003Date of Patent: January 29, 2008Assignees: Merck & Co., Inc., Isis Pharmaceuticals, Inc.Inventors: David B. Olsen, Balkrishen Bhat, Phillip Dan Cook
-
Patent number: 7157078Abstract: This invention relates to devices, kits, and methods for eliminating termite colonies. The kits, devices, and methods employ a termiticidal bait matrix containing a) a termiticide selected such that the termiticide causes death to about 50 to about 100% of termites within about 24 to about 84 days after the termites begin to ingest the termiticide or the bait matrix comprising the termiticide, b) a cellulose containing material, and c) water. The termiticidal bait matrix can be used in a bait station installed in the ground. The kits are suitable to be used by consumers in their homes.Type: GrantFiled: February 2, 2004Date of Patent: January 2, 2007Assignee: The University of Florida Research Foundation, Inc.Inventors: Philip Frederick Brode, III, Garry Steven Garren, Leo Timothy Laughlin, Randall Stryker Matthews, Dale Edwin Barker, Daniel James Kinne, Gary Eugene McKibben, Christopher Miles Miller, Timothy Robert Probst
-
Patent number: 7097860Abstract: A method of reducing inflammation in a variety of disorders by using an intraperitoneal solution of magnesium. The solution can be used for treating inflammatory and inflammation-related disorders in animals and/or humans. Application of the solution reduces inflammation and thereby assists in the healing process. An alternative method involves the intraperitoneal administration of a solution containing magnesium salts. Another alternative method provides for treatment of inflammatory and inflammation-related disorders in animals by way of intraperitoneal administration of a solution containing magnesium salts, methenamine or its salts and dextrose. The method further provides the use of methenamine or its salts and/or dextrose in combination with magnesium.Type: GrantFiled: May 16, 2002Date of Patent: August 29, 2006Inventors: Aaron Moshenyat, Anna Moshenyat, Reuven Moshenyat, Yitzchak Moshenyat
-
Patent number: 7045531Abstract: The invention relates to the identification of pharmacological agents to be used in the treatment of Alzheimer's disease and related pathological conditions. Methods and compositions for treatment of conditions caused by amyloidosis, A?-mediated ROS formation, or both, such as Alzheimer's disease, are disclosed.Type: GrantFiled: March 11, 1998Date of Patent: May 16, 2006Assignee: The General Hospital CorporationInventors: Ashley I. Bush, Xudong Huang, Craig S. Atwood, Rudolph E. Tanzi
-
Patent number: 7008903Abstract: The present invention provides a composition comprising synergistic amounts of a compound of the formula (I) wherein X, E, R, A and Z are as defined herein, and at least one fungicidal active compound as defined herein. The compositions of the present invention find use as pesticides.Type: GrantFiled: June 3, 2002Date of Patent: March 7, 2006Assignee: Bayer AktiengesellschaftInventors: Stefan Dutzmann, Christoph Erdelen, Wolfram Andersch, Heinz-Wilhelm Dehne, Jürgen Hartwig, Klaus Stenzel, Wolfgang Krämer
-
Patent number: 6716421Abstract: This invention relates to devices, kits, and methods for eliminating termite colonies. The kits, devices, and methods employ a termiticidal bait matrix containing a) a termiticide selected such that the termiticide causes death to about 50 to about 100% of termites within about 24 to about 84 days after the termites begin to ingest the termiticide or the bait matrix comprising the termiticide, b) a cellulose containing material, and c) water. The termiticidal bait matrix can be used in a bait station installed in the ground. The kits are suitable to be used by consumers in their homes.Type: GrantFiled: March 5, 2001Date of Patent: April 6, 2004Assignee: University of Florida Research Foundation, Inc.Inventors: Philip Frederick Brode, III, Garry Steven Garrett, Leo Timothy Laughlin, Randall Stryker Matthews, Dale Edwin Barker, Daniel James Kinne, Gary Eugene McKibben, Christopher Miles Miller, Timothy Robert Probst
-
Patent number: 6576633Abstract: Anhydrous, liquid antimicrobial compositions comprising quaternaries 1-(benzyl)-3,5,7-triaza-1-azoniaadamantane chloride, 1-(3-chloroallyl)-3,5,7-triaza-1-azoniaadamantane chloride and the cis- and cis/trans-isomers thereof, 1-(&agr;-(2-xylyl))-3,5,7-triaza-1-azoniaadamantane chloride and methyl 1-(3,5,7-triaza-1-azoniaadamantane chloride) acetate in admixture with an anhydrous carrier liquid and a thixotropic material are substantially stable to color changes, physical changes and/or chemical changes while under conventional storage conditions for extended time periods.Type: GrantFiled: February 22, 1996Date of Patent: June 10, 2003Assignee: The Dow Chemical CompanyInventors: Tracy L. Young, Philip J. Brondsema
-
Publication number: 20030018032Abstract: Substituted bicyclic imidazo-3-yl-amines and medicaments comprising these compounds, useful, inter alia, as analgesics.Type: ApplicationFiled: April 8, 2002Publication date: January 23, 2003Applicant: GRUENENTHAL GMBHInventors: Matthias Gerlach, Corinna Maul
-
Publication number: 20020197245Abstract: Antitumor combinations consisting of taxol or Taxotere or analogues thereof combined with at least one therapeutically useful substance for treating neoplastic diseases.Type: ApplicationFiled: April 30, 2002Publication date: December 26, 2002Applicant: Aventis Pharma, S.A.Inventor: Marie-Christine Bissery
-
Patent number: 6369051Abstract: This invention comprises methods of depression, anxiety, generalized anxiety disorder (GAD), hot flush, post partum depression, premenstrual syndrome, obesity, obsessive compulsive disorder, post-traumatic stress disorder, social phobia, disruptive behavior disorders, impulse control disorders, borderline personality disorder, chronic fatigue disorder, premature ejaculation, pain, attention deficit disorders, with and without hyperactivity, Gilles de la Tourette syndrome, bulimia nervosa, or Shy Drager Syndrome comprising administration of a selective serotonin reuptake inhibitor and compound of the formulae I or II: wherein Z is a moiety selected from the group of: wherein: R1 is selected from H, OH or the C1-C12 esters or C1-C12 alkyl ethers thereof, benzyloxy, or halogen; or C1-C4 halogenated ethers including trifluoromethyl ether and trichloromethyl ether; R2, R3, R4, R5, and R6 are H, OH or C1-C12 esters or C1-C12 alkyl ethers thereof, halogens, or C1-C4 halogenated eType: GrantFiled: June 29, 2001Date of Patent: April 9, 2002Assignee: American Home Products CorporationInventor: Simon Nicholas Jenkins
-
Patent number: 6340679Abstract: The present invention relates to acylguanidine derivatives of the formula I in which R1, R2, R4, Ar, X and n have the meanings indicated in the claims, their physiologically tolerable salts and their prodrugs. The compounds of the formula I are valuable pharmacologically active compounds. They are vitronectin receptor antagonists and inhibitors of cell adhesion. They inhibit, for example, bone resorption by osteoclasts and are suitable for the therapy and prophylaxis of diseases which are caused at least partially by an undesired extent of bone resorption, for example osteoporosis. The invention furthermore relates to processes for the preparation of compounds of the formula I, their use, in particular as active ingredients in pharmaceutical preparations, and pharmaceutical preparations comprising them.Type: GrantFiled: February 11, 2000Date of Patent: January 22, 2002Assignees: Aventis Pharma Deutschland GmbH, Genentech, Inc.Inventors: Anuschirwan Peyman, Jochen Knolle, Karl-Heinz Scheunemann, David William Will, Denis Carniato, Jean-Francois Gourvest, Thomas R. Gadek, Sarah Catherine Bodary
-
Publication number: 20010046995Abstract: Skin protection agents such as topical compositions which can prevent the passage of toxic chemicals through the skin, such as barrier creams. Formulations may contain hexamethylene tetramine or derivatives or analogues thereof, which react with alkylating agents such as sulfur mustard, and which are suitable for formulation into topical compositions. The formulations additionally may contain perfluorinated polymeric compounds which are effective barrier compounds for a range of toxic chemicals.Type: ApplicationFiled: January 23, 2001Publication date: November 29, 2001Applicant: The Secretary of State for Defence, Great Britain and Northern IrelandInventors: John Jenner, Colin N. Smith, Robert P. Chilcott, Christopher D. Lindsay
-
Patent number: 6323218Abstract: The invention relates to the identification of pharmacological agents to be used in the treatment of Alzheimer's disease and related pathological conditions and compositions for treatment of conditions caused by amyloidosis, A&bgr;-mediated formation of ROS, or both, such as Alzheimer's disease.Type: GrantFiled: March 11, 1998Date of Patent: November 27, 2001Assignee: The General Hospital CorporationInventors: Ashley I. Bush, Xudong Huang, Craig S. Atwood, Rudolph E. Tanzi
-
Patent number: 6251916Abstract: The present invention provides novel compounds and pharmaceutical compositions thereof useful in the treatment of pain. The compounds of the present invention are azaadamantanes, azanoradamantanes and azahomoadamantanes.Type: GrantFiled: May 9, 2000Date of Patent: June 26, 2001Assignee: UCB, S. A.Inventors: Gurmit Grewal, Anna Toy-Palmer, Xiong Cai, George Mark Latham
-
Patent number: 6183729Abstract: The present invention discloses stable vitamin C concentrates suitable for use in a multichamber dispenser. The compositions have a pH above about 5 and preferably should contain a xanthan and/or a carbomer as a viscosifier.Type: GrantFiled: December 10, 1998Date of Patent: February 6, 2001Assignee: Cosmoferm B.V.Inventors: Bertus Noordam, Luppo Edens
-
Patent number: 6043243Abstract: A pyrrolidine derivative or a salt thereof expressed by the following formula 1: ##STR1## wherein R.sub.1 is an alkenyl group; R.sub.2 is a lower alkoxy group or a halogen atom;R.sub.3 is a lower alkyl group;X is a group expressed by --O-- or --S--;Y is carbon or nitrogen atom;m is an integer of 1 to 3; andn is an integer of 0 to 2.The pyrrolidine derivative has an anti-ulcer effect or an antibacterial activity against Helicobacter pyroli, and has also high safety to be available for prevention or cure of ulcers.Type: GrantFiled: December 3, 1998Date of Patent: March 28, 2000Assignee: Shiseido Co., Ltd.Inventors: Chikao Nishino, Tomohiro Uetake
-
Patent number: 5716629Abstract: The invention is a composition for controlling microbiological growth which comprises a combination of 1-(3-chloroallyl)-3,5,7-triaza-1-azoniaadamantane and tetrahydro-3,5-dimethyl-2H-1,3,5-thiadiazine-2-thione. The invention has particular utility as a composition for controlling microbiological growth in a slurry of paper machine additives such as precipitated calcium carbonate which comprises adding to said slurry a combination of 1-(3-chloroallyl)-3,5,7-triaza-1-azoniaadamantane and tetrahydro-3,5-dimethyl-2H-1,3,5-thiadiazine-2-thione.The invention is also a method for controlling bacterial and fungal growth which comprises a combination of 1-(3-chloroallyl)-3,5,7-triaza-1-azoniaadamantane and tetrahydro-3,5-dimethyl-2H-1,3,5-thiadiazine-2-thione.Type: GrantFiled: August 8, 1996Date of Patent: February 10, 1998Assignee: Nalco Chemical CompanyInventors: Linda R. Robertson, Sasireka S. Ramesh
-
Patent number: 5668083Abstract: 3-Isothiazolone compositions which are stable, free from turbidity, and do not corrode metal storage containers are disclosed. These compositions further have no possibility of coagulating latex or generating nitrosamine.Type: GrantFiled: July 18, 1996Date of Patent: September 16, 1997Assignee: Rohm and Haas CompanyInventor: Masahiro Matsumoto
-
Patent number: 5637587Abstract: This invention provides a surprisingly efficacious combination useful for inhibiting microorganism growth, particularly in aqueous slurries containing mineral ore. In particular embodiments, the invention provides an antimicrobial composition comprising 1-(3-chloroallyl)-3,5,7 triaza-1-azoniaadamantane chloride and 2-bromo-2-nitropropane-1,3-diol. The invention also provides a method for inhibiting microbial growth in an aqueus mineral or ore slurry, e.g. a kaolin slurry. The method includes the step of adding to the slurry a microbiocidal composition of 1-(3-chloroallyl)-3,5,7 triaza-1-azoniaadamantane chloride and 2-bromo-2-nitropropane-1,3-diol.Type: GrantFiled: February 7, 1996Date of Patent: June 10, 1997Assignee: Nalco Chemical CompanyInventors: Anthony E. Gross, Nancy L. Casselman